Abdominal Aortic Aneurysm, Deep Vein Thrombosis
Conditions
Brief summary
Arterial and venous thrombi play an important role in various vascular diseases such as myocardial infarction, stroke, transient ischemic attacks (TIA) and pulmonary embolism. These thromboembolic disorders are the leading causes of morbidity and mortality worldwide. A non-invasive method for the quantitative and effective detection of thrombi in the whole body has not yet been established. In spite of the available techniques, 30% to 40% of ischemic strokes cryptogenic (undetermined cause, the source of thromboembolism is never identified). Possible causes of cryptogenic stroke atherosclerosis include in the aortic arch or intracranial arteries. A plaque in the arch or other large vessels could be an important source of cryptogenic strokes, however, are those difficult to detect by routine methods. The approach of thrombus targeted molecular imaging could identify potentially troublesome plaques early on before they become a dangerous rupture. The hypothesis is that the radiotracer 18F-arterial GP1 and venous thrombi using positron emission tomography (PET) can be made visible. The primary goal is the potential applicability of the substance as a PET tracer for diagnosing thrombi.
Detailed description
This is a first in man study with which we are testing the feasibility of the use of this radiopharmaceutical product to visualize a thrombus.
Interventions
DRUG[18F]-GP1
Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
Sponsors
Life Molecular Imaging SA
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with AAA (diameter \>3.5cm in duplex sonography) or acute DVT. * Male and female patients 18 years and older, * Signed Informed Consent after being informed
Exclusion criteria
* contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, * women who are pregnant or breast feeding, * women with the intention to become pregnant during the course of the study, * other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease), * renal clearance \< 30 mL/min * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject, * participation in another study with an investigational drug during the present study and 7 days thereafter. * enrolment of the investigator, his family members, employees and other dependent persons * last systemic treatment with GP IIb/IIIa antagonists should not have been applied within 48 h before performing study exam
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of biodistribution of [18F]-GP1 and its properties as a PET imaging agent for detection of abdominal aortic aneurysm (AAA) and deep vein thrombosis (DVT). | 12 Months | Biodistribution and diagnostic properties of the new Tracer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Calculation of the effective dose to the patient according to the tissue distribution data of [18F]-GP1 (Dosimetry) | 12 Months | Dosimtery assessment of the new Tracer |
Countries
Switzerland
Outcome results
None listed